Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: technetium tc-99m apcitide

« Back to Dashboard
Technetium tc-99m apcitide is the generic ingredient in one branded drug marketed by Cis Bio Intl Sa and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has two hundred and forty-five patent family members in twenty-five countries.

There are four drug master file entries for technetium tc-99m apcitide.

Summary for Generic Name: technetium tc-99m apcitide

Drug Master File Entries: see list4

Clinical Trials for: technetium tc-99m apcitide

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cis Bio Intl Sa
technetium tc-99m apcitide
INJECTABLE;INJECTION020887-001Sep 14, 1998DISCNNo5,645,815<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: technetium tc-99m apcitide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,932,189 Cyclic peptide somatostatin analogs<disabled in preview>
6,093,383 Bisamine bisthiol radiolabel binding moieties<disabled in preview>
5,780,007 Technetium-99m labeled peptides for imaging<disabled in preview>
7,238,340Monoamine, diamide, thiol-containing metal chelating agents<disabled in preview>
5,833,942 Technetium-99m labeled somatostatin-derived peptides for imaging and therapeutic uses<disabled in preview>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: technetium tc-99m apcitide

Country Document Number Publication Date
China1087630Jul 17, 2002
European Patent Office0614379Feb 13, 2002
European Patent Office0720621Feb 07, 2001
Germany69232418Oct 31, 2002
European Patent Office0637968Sep 08, 1999
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn